Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.47 |
| ▸ | MTOR | P42345 | 6/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12600392 | 0.84 | MAPK1 (0.63) | MAPK1L3MBTL1MEN1KMT2APABPC1 | |
| SCHEMBL12600402 | 0.83 | MAPK1 (0.49) | MAPK1L3MBTL1MEN1KMT2APABPC1 | |
| SCHEMBL12600098 | 0.83 | MAPK1 (0.49) | MAPK1L3MBTL1MEN1KMT2APABPC1 | |
| SCHEMBL12600722 | 0.80 | PIK3CA (0.53) | MAPTNPC1PIK3CAMTORPIK3R1 | |
| SCHEMBL12601028 | 0.79 | MAPK1 (0.51) | MAPK1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL6347219 | 0.77 | MEN1 (0.62) | MAPK1L3MBTL1MEN1KMT2APABPC1 | |
| SCHEMBL13563199 | 0.77 | NPC1 (0.48) | MEN1KMT2APABPC1MAPTNPC1 | |
| SCHEMBL117981 | 0.75 | FGFR4 (0.51) | MAPK1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL31315323 | 0.75 | FGFR4 (0.51) | MAPK1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL29532865 | 0.73 | FGFR4 (0.48) | MAPK1L3MBTL1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533983-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-03 | — | — | US | disclosed |
| EP-2518066-B1 | NOVEL ANTI-PLATELET AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8703760-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703760-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| EP-2518066-A1 | NOVEL ANTI-PLATELET AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258951-A1 | NOVEL ANTIPLATELET AGENT | Mitsubishi Tanage Pharma Corporation (JP) | 2012-10-11 | — | — | US | disclosed |
| WO-2011074658-A1 | NOVEL ANTI-PLATELET AGENT | 田辺三菱製薬株式会社 (JP) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | F12, TBXA2R, F11 | MAPK1 447/4885L3MBTL1 3698/4885MEN1 2309/4885 |
| US-20120258951-A1 | NOVEL ANTIPLATELET AGENT | F12, TBXA2R, F11 | MAPK1 447/4885L3MBTL1 3698/4885MEN1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.